FDA Regulatory Pathways for Expedited Drug Development and Approval

While expedited FDA approval pathways can speed patient access to promising new cancer therapies, they also increase the risk of approving drugs with uncertain benefits or safety issues. To mitigate these risks, FDA should provide clearer communication about the nature of expedited approvals, rapidly update drug labels when new evidence emerges, and take action to ensure sponsors complete confirmatory trials in a timely manner.